Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 451 entries
Sorted by: Best Match Show Resources per page
Refractory Angioedema in a Patient with Systemic Lupus Erythematosus.

Iranian journal of medical sciences

Habibagahi Z, Ruzbeh J, Yarmohammadi V, Kamali M, Rastegar MH.
PMID: 26170526
Iran J Med Sci. 2015 Jul;40(4):372-5.

Angioedema secondary to C1 inhibitor deficiency has been rarely reported to be associated with systemic lupus erythematosus. A genetic defect of C1 inhibitor produces hereditary angioedema, which is usually presented with cutaneous painless edema, but edema of the genital...

Cite
Habibagahi Z, Ruzbeh J, Yarmohammadi V, et al. Refractory Angioedema in a Patient with Systemic Lupus Erythematosus. Iran J Med Sci. 2015;40(4):372-5
Habibagahi, Z., Ruzbeh, J., Yarmohammadi, V., Kamali, M., & Rastegar, M. H. (2015). Refractory Angioedema in a Patient with Systemic Lupus Erythematosus. Iranian journal of medical sciences, 40(4), 372-5.
Habibagahi, Zahra, et al. "Refractory Angioedema in a Patient with Systemic Lupus Erythematosus." Iranian journal of medical sciences vol. 40,4 (2015): 372-5.
Habibagahi Z, Ruzbeh J, Yarmohammadi V, Kamali M, Rastegar MH. Refractory Angioedema in a Patient with Systemic Lupus Erythematosus. Iran J Med Sci. 2015 Jul;40(4):372-5. PMID: 26170526; PMCID: PMC4487465.
Copy Download .nbib Format: NLM
Targeting renin-angiotensin system in malignant hypertension in atypical hemolytic uremic syndrome.

Indian journal of nephrology

Raghunathan V, Sethi SK, Dragon-Durey MA, Dhaliwal M, Raina R, Jha P, Bansal SB, Kher V.
PMID: 28356668
Indian J Nephrol. 2017 Mar-Apr;27(2):136-140. doi: 10.4103/0971-4065.181462.

Hypertension is common in hemolytic uremic syndrome (HUS) and often difficult to control. Local renin-angiotensin activation is believed to be an important part of thrombotic microangiopathy, leading to a vicious cycle of progressive renal injury and intractable hypertension. This...

Cite
Raghunathan V, Sethi SK, Dragon-Durey MA, et al. Targeting renin-angiotensin system in malignant hypertension in atypical hemolytic uremic syndrome. Indian J Nephrol. 2017;27(2):136-140doi: 10.4103/0971-4065.181462.
Raghunathan, V., Sethi, S. K., Dragon-Durey, M. A., Dhaliwal, M., Raina, R., Jha, P., Bansal, S. B., & Kher, V. (2017). Targeting renin-angiotensin system in malignant hypertension in atypical hemolytic uremic syndrome. Indian journal of nephrology, 27(2), 136-140. https://doi.org/10.4103/0971-4065.181462
Raghunathan, V, et al. "Targeting renin-angiotensin system in malignant hypertension in atypical hemolytic uremic syndrome." Indian journal of nephrology vol. 27,2 (2017): 136-140. doi: https://doi.org/10.4103/0971-4065.181462
Raghunathan V, Sethi SK, Dragon-Durey MA, Dhaliwal M, Raina R, Jha P, Bansal SB, Kher V. Targeting renin-angiotensin system in malignant hypertension in atypical hemolytic uremic syndrome. Indian J Nephrol. 2017 Mar-Apr;27(2):136-140. doi: 10.4103/0971-4065.181462. PMID: 28356668; PMCID: PMC5358156.
Copy Download .nbib Format: NLM
[Effect of Fixed Lercanidipine/Enalapril Combination on 24-Hour Blood Pressure Profile in Elderly Patients With Arterial Hypertension].

Kardiologiia

Gosteva EV, Vasileva LV.
PMID: 28294808
Kardiologiia. 2015 Feb;55(2):32-36.

We studied effect of therapy with fixed combination of lercanidipine and enalapril on 24-hour blood pressure (BP) profile in 34 elderly patients (mean age 76.4+/-5.2 years, 14 men, 20 women) with degree II hypertension. After clinical examination patients were...

Cite
Gosteva EV, Vasileva LV. [Effect of Fixed Lercanidipine/Enalapril Combination on 24-Hour Blood Pressure Profile in Elderly Patients With Arterial Hypertension]. Kardiologiia. 2015;55(2):32-36
Gosteva, E. V., & Vasileva, L. V. (2015). [Effect of Fixed Lercanidipine/Enalapril Combination on 24-Hour Blood Pressure Profile in Elderly Patients With Arterial Hypertension]. Kardiologiia, 55(2), 32-36.
Gosteva, E V, and Vasileva, L V. "[Effect of Fixed Lercanidipine/Enalapril Combination on 24-Hour Blood Pressure Profile in Elderly Patients With Arterial Hypertension]." Kardiologiia vol. 55,2 (2015): 32-36.
Gosteva EV, Vasileva LV. [Effect of Fixed Lercanidipine/Enalapril Combination on 24-Hour Blood Pressure Profile in Elderly Patients With Arterial Hypertension]. Kardiologiia. 2015 Feb;55(2):32-36. Russian. PMID: 28294808.
Copy Download .nbib Format: NLM
Evaluation of the antioxidant properties of the angiotensin-converting enzyme inhibitor, captopril and the nucleotide enhancing agent, acadesine.

Redox report : communications in free radical research

Wasil M, Kelly FJ.
PMID: 27405835
Redox Rep. 1995 Nov;1(5):361-7. doi: 10.1080/13510002.1995.11747012.

The angiotensin-converting enzyme inhibitor, captopril and the nucleotide enhancing agent, acadesine, protect myocardial tissue from ischaemia/reperfusion-induced injury. Although both drugs have well established, independent mechanisms of cardiac protection, they may also have antioxidant activity which could contribute to their...

Cite
Wasil M, Kelly FJ. Evaluation of the antioxidant properties of the angiotensin-converting enzyme inhibitor, captopril and the nucleotide enhancing agent, acadesine. Redox Rep. 1995;1(5):361-7doi: 10.1080/13510002.1995.11747012.
Wasil, M., & Kelly, F. J. (1995). Evaluation of the antioxidant properties of the angiotensin-converting enzyme inhibitor, captopril and the nucleotide enhancing agent, acadesine. Redox report : communications in free radical research, 1(5), 361-7. https://doi.org/10.1080/13510002.1995.11747012
Wasil, M, and Kelly, F J. "Evaluation of the antioxidant properties of the angiotensin-converting enzyme inhibitor, captopril and the nucleotide enhancing agent, acadesine." Redox report : communications in free radical research vol. 1,5 (1995): 361-7. doi: https://doi.org/10.1080/13510002.1995.11747012
Wasil M, Kelly FJ. Evaluation of the antioxidant properties of the angiotensin-converting enzyme inhibitor, captopril and the nucleotide enhancing agent, acadesine. Redox Rep. 1995 Nov;1(5):361-7. doi: 10.1080/13510002.1995.11747012. PMID: 27405835.
Copy Download .nbib Format: NLM
Bioequivalence study of two formulations of enalapril, at a single oral dose of 20 mg (tablets): A randomized, two-way, open-label, crossover study in healthy volunteers.

Current therapeutic research, clinical and experimental

Portolés A, Terleira A, Almeida S, García-Arenillas M, Caturla MC, Filipe A, Vargas E.
PMID: 24936102
Curr Ther Res Clin Exp. 2004 Jan;65(1):34-46. doi: 10.1016/S0011-393X(04)90003-3.

BACKGROUND: Enalapril maleate is the monoethyl ester prodrug of enalapril- at, an angiotensin-converting enzyme inhibitor indicated in the management of essential and renovascular hypertension, and in the treatment of congestive heart failure and in asymptomatic patients with left ventricular...

Cite
Portolés A, Terleira A, Almeida S, et al. Bioequivalence study of two formulations of enalapril, at a single oral dose of 20 mg (tablets): A randomized, two-way, open-label, crossover study in healthy volunteers. Curr Ther Res Clin Exp. 2004;65(1):34-46doi: 10.1016/S0011-393X(04)90003-3.
Portolés, A., Terleira, A., Almeida, S., García-Arenillas, M., Caturla, M. C., Filipe, A., & Vargas, E. (2004). Bioequivalence study of two formulations of enalapril, at a single oral dose of 20 mg (tablets): A randomized, two-way, open-label, crossover study in healthy volunteers. Current therapeutic research, clinical and experimental, 65(1), 34-46. https://doi.org/10.1016/S0011-393X(04)90003-3
Portolés, Antonio, et al. "Bioequivalence study of two formulations of enalapril, at a single oral dose of 20 mg (tablets): A randomized, two-way, open-label, crossover study in healthy volunteers." Current therapeutic research, clinical and experimental vol. 65,1 (2004): 34-46. doi: https://doi.org/10.1016/S0011-393X(04)90003-3
Portolés A, Terleira A, Almeida S, García-Arenillas M, Caturla MC, Filipe A, Vargas E. Bioequivalence study of two formulations of enalapril, at a single oral dose of 20 mg (tablets): A randomized, two-way, open-label, crossover study in healthy volunteers. Curr Ther Res Clin Exp. 2004 Jan;65(1):34-46. doi: 10.1016/S0011-393X(04)90003-3. PMID: 24936102; PMCID: PMC4052970.
Copy Download .nbib Format: NLM
Modifying the Interagency Emergency Health Kit to include treatment for non-communicable diseases in natural disasters and complex emergencies.

BMJ global health

Tonelli M, Wiebe N, Nadler B, Darzi A, Rasheed S.
PMID: 28588970
BMJ Glob Health. 2016 Oct 20;1(3):e000128. doi: 10.1136/bmjgh-2016-000128. eCollection 2016.

The Interagency Emergency Health Kit (IEHK) provides a standard package of medicines and simple medical devices for aid agencies to use in emergencies such as disasters and armed conflicts. Despite the increasing burden of non-communicable diseases (NCDs) in such...

Cite
Tonelli M, Wiebe N, Nadler B, et al. Modifying the Interagency Emergency Health Kit to include treatment for non-communicable diseases in natural disasters and complex emergencies. BMJ Glob Health. 2016;1(3):e000128doi: 10.1136/bmjgh-2016-000128.
Tonelli, M., Wiebe, N., Nadler, B., Darzi, A., & Rasheed, S. (2016). Modifying the Interagency Emergency Health Kit to include treatment for non-communicable diseases in natural disasters and complex emergencies. BMJ global health, 1(3), e000128. https://doi.org/10.1136/bmjgh-2016-000128
Tonelli, Marcello, et al. "Modifying the Interagency Emergency Health Kit to include treatment for non-communicable diseases in natural disasters and complex emergencies." BMJ global health vol. 1,3 (2016): e000128. doi: https://doi.org/10.1136/bmjgh-2016-000128
Tonelli M, Wiebe N, Nadler B, Darzi A, Rasheed S. Modifying the Interagency Emergency Health Kit to include treatment for non-communicable diseases in natural disasters and complex emergencies. BMJ Glob Health. 2016 Oct 20;1(3):e000128. doi: 10.1136/bmjgh-2016-000128. eCollection 2016. PMID: 28588970; PMCID: PMC5321368.
Copy Download .nbib Format: NLM
A Liquid Chromatography-Tandem Mass Spectrometry Method for Evaluation of Two Brands of Enalapril 20 mg Tablets in Healthy Human Volunteers.

Journal of analytical methods in chemistry

Dayyih WA, Hamad M, Awwad AA, Mallah E, Zakarya Z, Dayyih AA, Arafat T.
PMID: 28894622
J Anal Methods Chem. 2017;2017:8489471. doi: 10.1155/2017/8489471. Epub 2017 Aug 15.

Enalapril is an angiotensin-converting enzyme inhibitor used for treatment of hypertension and chronic heart disease. Enalaprilat is its active metabolite responsible for the activity. This study aimed to develop and validate a method for enalapril and enalaprilat analysis and...

Cite
Dayyih WA, Hamad M, Awwad AA, et al. A Liquid Chromatography-Tandem Mass Spectrometry Method for Evaluation of Two Brands of Enalapril 20 mg Tablets in Healthy Human Volunteers. J Anal Methods Chem. 2017;2017:8489471doi: 10.1155/2017/8489471.
Dayyih, W. A., Hamad, M., Awwad, A. A., Mallah, E., Zakarya, Z., Dayyih, A. A., & Arafat, T. (2017). A Liquid Chromatography-Tandem Mass Spectrometry Method for Evaluation of Two Brands of Enalapril 20 mg Tablets in Healthy Human Volunteers. Journal of analytical methods in chemistry, 20178489471. https://doi.org/10.1155/2017/8489471
Dayyih, Wael Abu, et al. "A Liquid Chromatography-Tandem Mass Spectrometry Method for Evaluation of Two Brands of Enalapril 20 mg Tablets in Healthy Human Volunteers." Journal of analytical methods in chemistry vol. 2017 (2017): 8489471. doi: https://doi.org/10.1155/2017/8489471
Dayyih WA, Hamad M, Awwad AA, Mallah E, Zakarya Z, Dayyih AA, Arafat T. A Liquid Chromatography-Tandem Mass Spectrometry Method for Evaluation of Two Brands of Enalapril 20 mg Tablets in Healthy Human Volunteers. J Anal Methods Chem. 2017;2017:8489471. doi: 10.1155/2017/8489471. Epub 2017 Aug 15. PMID: 28894622; PMCID: PMC5574226.
Copy Download .nbib Format: NLM
Nephroprotective effects of enalapril after [177Lu]-DOTATATE therapy using serial renal scintigraphies in a murine model of radiation-induced nephropathy.

EJNMMI research

Ilhan H, Wang H, Gildehaus FJ, Wängler C, Herrler T, Todica A, Schlichtiger J, Cumming P, Bartenstein P, Hacker M, Haug AR.
PMID: 27515447
EJNMMI Res. 2016 Dec;6(1):64. doi: 10.1186/s13550-016-0219-2. Epub 2016 Aug 11.

BACKGROUND: Radiation-induced nephropathy is still dose limiting in radionuclide therapy of neuroendocrine tumors. We investigated the nephroprotective potential of the angiotensine converting enzyme inhibiting drug enalpril after [177Lu]-DOTATATE therapy in a murine model of radiation-induced nephropathy by renal scintigraphy....

Cite
Ilhan H, Wang H, Gildehaus FJ, et al. Nephroprotective effects of enalapril after [177Lu]-DOTATATE therapy using serial renal scintigraphies in a murine model of radiation-induced nephropathy. EJNMMI Res. 2016;6(1):64doi: 10.1186/s13550-016-0219-2.
Ilhan, H., Wang, H., Gildehaus, F. J., Wängler, C., Herrler, T., Todica, A., Schlichtiger, J., Cumming, P., Bartenstein, P., Hacker, M., & Haug, A. R. (2016). Nephroprotective effects of enalapril after [177Lu]-DOTATATE therapy using serial renal scintigraphies in a murine model of radiation-induced nephropathy. EJNMMI research, 6(1), 64. https://doi.org/10.1186/s13550-016-0219-2
Ilhan, Harun, et al. "Nephroprotective effects of enalapril after [177Lu]-DOTATATE therapy using serial renal scintigraphies in a murine model of radiation-induced nephropathy." EJNMMI research vol. 6,1 (2016): 64. doi: https://doi.org/10.1186/s13550-016-0219-2
Ilhan H, Wang H, Gildehaus FJ, Wängler C, Herrler T, Todica A, Schlichtiger J, Cumming P, Bartenstein P, Hacker M, Haug AR. Nephroprotective effects of enalapril after [177Lu]-DOTATATE therapy using serial renal scintigraphies in a murine model of radiation-induced nephropathy. EJNMMI Res. 2016 Dec;6(1):64. doi: 10.1186/s13550-016-0219-2. Epub 2016 Aug 11. PMID: 27515447; PMCID: PMC4980865.
Copy Download .nbib Format: NLM
Nodular glomerulosclerosis in a patient with cystic fibrosis, but not diabetes mellitus: A paediatric case.

Respiratory medicine case reports

Lalayiannis AD, Thompson C, Malcomson R, Milford DV.
PMID: 27489763
Respir Med Case Rep. 2016 Jul 14;19:58-60. doi: 10.1016/j.rmcr.2016.07.005. eCollection 2016.

BACKGROUND: Nodular glomerulosclerosis is seen in insulin dependent diabetic patients with nephropathy. Kimmelstiel-Wilson nodules on biopsy are considered pathognomonic. Diabetic nephropathy is a spectrum of glomerular and tubular disease which correlates with the duration of the diabetes and the...

Cite
Lalayiannis AD, Thompson C, Malcomson R, et al. Nodular glomerulosclerosis in a patient with cystic fibrosis, but not diabetes mellitus: A paediatric case. Respir Med Case Rep. 2016;19:58-60doi: 10.1016/j.rmcr.2016.07.005.
Lalayiannis, A. D., Thompson, C., Malcomson, R., & Milford, D. V. (2016). Nodular glomerulosclerosis in a patient with cystic fibrosis, but not diabetes mellitus: A paediatric case. Respiratory medicine case reports, 1958-60. https://doi.org/10.1016/j.rmcr.2016.07.005
Lalayiannis, A D, et al. "Nodular glomerulosclerosis in a patient with cystic fibrosis, but not diabetes mellitus: A paediatric case." Respiratory medicine case reports vol. 19 (2016): 58-60. doi: https://doi.org/10.1016/j.rmcr.2016.07.005
Lalayiannis AD, Thompson C, Malcomson R, Milford DV. Nodular glomerulosclerosis in a patient with cystic fibrosis, but not diabetes mellitus: A paediatric case. Respir Med Case Rep. 2016 Jul 14;19:58-60. doi: 10.1016/j.rmcr.2016.07.005. eCollection 2016. PMID: 27489763; PMCID: PMC4961824.
Copy Download .nbib Format: NLM
In Vivo Effects of Bradykinin B2 Receptor Agonists with Varying Susceptibility to Peptidases.

Frontiers in pharmacology

Jean M, Gera L, Charest-Morin X, Marceau F, Bachelard H.
PMID: 26793104
Front Pharmacol. 2016 Jan 12;6:306. doi: 10.3389/fphar.2015.00306. eCollection 2015.

We reported evidence of bradykinin (BK) regeneration from C-terminal extended BK sequences that behave as peptidase-activated B2 receptor (B2R) agonists. Further to these in vitro studies, we carried out in vivo experiments to verify hemodynamic effects of BK analogs...

Cite
Jean M, Gera L, Charest-Morin X, et al. In Vivo Effects of Bradykinin B2 Receptor Agonists with Varying Susceptibility to Peptidases. Front Pharmacol. 2016;6:306doi: 10.3389/fphar.2015.00306.
Jean, M., Gera, L., Charest-Morin, X., Marceau, F., & Bachelard, H. (2015). In Vivo Effects of Bradykinin B2 Receptor Agonists with Varying Susceptibility to Peptidases. Frontiers in pharmacology, 6306. https://doi.org/10.3389/fphar.2015.00306
Jean, Mélissa, et al. "In Vivo Effects of Bradykinin B2 Receptor Agonists with Varying Susceptibility to Peptidases." Frontiers in pharmacology vol. 6 (2015): 306. doi: https://doi.org/10.3389/fphar.2015.00306
Jean M, Gera L, Charest-Morin X, Marceau F, Bachelard H. In Vivo Effects of Bradykinin B2 Receptor Agonists with Varying Susceptibility to Peptidases. Front Pharmacol. 2016 Jan 12;6:306. doi: 10.3389/fphar.2015.00306. eCollection 2015. PMID: 26793104; PMCID: PMC4709452.
Copy Download .nbib Format: NLM
A retrospective study of antihypertensives in pemphigus: a still unchartered odyssey particularly between thiols, amides and phenols.

Archives of medical science : AMS

Pietkiewicz P, Gornowicz-Porowska J, Bowszyc-Dmochowska M, Dmochowski M.
PMID: 26528346
Arch Med Sci. 2015 Oct 12;11(5):1021-7. doi: 10.5114/aoms.2015.54857.

INTRODUCTION: Autoimmune pemphigus diseases comprise several entities with serious prognoses, including the pemphigus vulgaris (PV) group and pemphigus foliaceus (PF) group. Antihypertensives are suspected to be one of the factors triggering/sustaining pemphigus. Here, the data of pemphigus patients regarding...

Cite
Pietkiewicz P, Gornowicz-Porowska J, Bowszyc-Dmochowska M, et al. A retrospective study of antihypertensives in pemphigus: a still unchartered odyssey particularly between thiols, amides and phenols. Arch Med Sci. 2015;11(5):1021-7doi: 10.5114/aoms.2015.54857.
Pietkiewicz, P., Gornowicz-Porowska, J., Bowszyc-Dmochowska, M., & Dmochowski, M. (2015). A retrospective study of antihypertensives in pemphigus: a still unchartered odyssey particularly between thiols, amides and phenols. Archives of medical science : AMS, 11(5), 1021-7. https://doi.org/10.5114/aoms.2015.54857
Pietkiewicz, Paweł, et al. "A retrospective study of antihypertensives in pemphigus: a still unchartered odyssey particularly between thiols, amides and phenols." Archives of medical science : AMS vol. 11,5 (2015): 1021-7. doi: https://doi.org/10.5114/aoms.2015.54857
Pietkiewicz P, Gornowicz-Porowska J, Bowszyc-Dmochowska M, Dmochowski M. A retrospective study of antihypertensives in pemphigus: a still unchartered odyssey particularly between thiols, amides and phenols. Arch Med Sci. 2015 Oct 12;11(5):1021-7. doi: 10.5114/aoms.2015.54857. PMID: 26528346; PMCID: PMC4624747.
Copy Download .nbib Format: NLM
Adherence to EBM guidelines in clinical practice.

The International journal of risk & safety in medicine

Khafizianova RKh, Burykin IM.
PMID: 26639710
Int J Risk Saf Med. 2015;27:S53-4. doi: 10.3233/JRS-150687.

BACKGROUND: Adequate and rational pharmacotherapy is an important element of rehabilitation of patients with myocardial infarction. Orders of the Ministry of Health of the Russian Federation, domestic and international guidelines, and scientific publications - all contain a complete algorithm...

Cite
Khafizianova RKh, Burykin IM. Adherence to EBM guidelines in clinical practice. Int J Risk Saf Med. 2015;27:S53-4doi: 10.3233/JRS-150687.
Khafizianova, R. K. h., & Burykin, I. M. (2015). Adherence to EBM guidelines in clinical practice. The International journal of risk & safety in medicine, 27S53-4. https://doi.org/10.3233/JRS-150687
Khafizianova, R Kh, and Burykin, I M. "Adherence to EBM guidelines in clinical practice." The International journal of risk & safety in medicine vol. 27 (2015): S53-4. doi: https://doi.org/10.3233/JRS-150687
Khafizianova RKh, Burykin IM. Adherence to EBM guidelines in clinical practice. Int J Risk Saf Med. 2015;27:S53-4. doi: 10.3233/JRS-150687. PMID: 26639710.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 451 entries